Sézary's disease: Difference between revisions
No edit summary |
No edit summary |
||
Line 57: | Line 57: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Oncology stub]] | [[Category:Oncology stub]] | ||
[[de:Sézary-Syndrom]] | [[de:Sézary-Syndrom]] | ||
[[ja:セザリー症候群]] | [[ja:セザリー症候群]] |
Revision as of 15:23, 21 September 2012
Template:DiseaseDisorder infobox Template:Sezary's disease Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Cutaneous T-cell lymphoma; mycosis fungoides; sezary syndrome
Overview
Sézary's disease (or "Sézary syndrome") is a type of cutaneous lymphoma characterized by Albert Sézary. [1]. "Sézary's cells" are T-cells that have pathological quantities of mucopolysaccharides. Sézary's disease is sometimes considered a late stage of mycosis fungoides. Sezary syndrome and Mycosis Fungoides are T-cell lymphomas whose primary manifestation is in the skin.
Etiology
HTLV has thought to have been associated with both of the above cutaneous mycoses.
Symptoms
The hallmark symptoms for Sézary's disease are
- Generalized erythroderma
- Lymphadenopathy
- Atypical T-cells ("Sezary cells") in the peripheral blood.
Treatment
Vorinostat (Zolinza®) is a second-line drug for CTCL. Treatments are often used in combination.